Blueprint Medicines Corp

Blueprint Medicines Corp is an American pharmaceutical and medical manufacturing company based in Cambridge, Massachusetts. Established in 2008, the firm focuses on the identification of kinases that act as drivers of genomically defined cancers and hematologic disorders. Operating globally, the firm uses its research to develop precision therapies that aim to provide significant clinical responses in patients and greatly increase quality of life. The firm’s products include AYVAKIT/AYVAKYT (avapritinib), which is used for the treatment of a rare hematologic disorder called systemic mastocytosis (SM), characterised by the production of excess mast cells leading to the accumulation of mast cells in the bone marrow and other organs. Blueprint also produces GAVRETO (pralsetinib), an oral therapy for patients with RET-positive metastatic non-small lung cancer and advanced thyroid cancer. The company has a number of products in the pipeline at various clinical and pre-clinical phases, primarily focused on improving outcomes for patients living with genomically defined cancers, advanced cancers, and hematologic disorders. The firm worked in collaboration with Genentech, a member of the Roche Group, to develop and commercialise pralsetinib as a therapy for patients with RET-altered cancers. Blueprint Medicines Corp is listed on the NASDAQ, where it trades under the stock ticker BPMC. Learn more about the performance of BPMC share prices on eToro.